GROW - School for Oncology and Reproduction
To all of our (scientific) staff and (external) PhD's: please note that our GROW Community is our main communication channel.
GROW focuses on research and teaching of genetic and cellular mechanisms, as well as environmental and life-style factors that underlie normal (embryonic and fetal) and abnormal (cancer) growth. The emphasis is on basic and translational research, aiming at innovative approaches for individualizing prevention, patient diagnosis, and treatment for genetically determined diseases and cancer.
- Focus on genetics, cancer, fertility, early development, and ethics
- Led by Prof.dr. Manon van Engeland
- Part of the Maastricht UMC+ Comprehensive Cancer Center
- ± 50 PhD defenses and 675 publications every year
- 535 scientists, including 375 PhD students, 9 affiliation professors
GROW researcher Lizza Hendriks appointed member of The Young Academy
In 2021, Lizza Hendriks, Assistant Professor at research institute GROW, School for Oncology and Reproduction of Maastricht University will join The Young Academy. This is a platform of the Royal Netherlands Academy of Sciences, where young top scientists from different disciplines work together in the field of research and science policy.
About Lizza Hendriks
Dr Lizza Hendriks (1981) has worked at Maastricht UMC + as a lung specialist since 2012. Her focus area is thoracic oncology, in particular prevention and optimal treatment of brain metastases in lung cancer. In 2016, she earned her PhD on this topic. To gain in-depth knowledge of both research and medical oncology, she worked one year as a postdoc at the Gustave Roussy Institute in France.
Since 2019, Dr Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht. She does this in addition to her clinical tasks and teaching. Currently, Dr Hendriks supervises six PhD students. Her research ambition is to develop personalised therapy (in terms of biomarkers and psychosocial and cognitive capacity) with a focus on prevention/optimal treatment of brain metastases, while preserving neurocognition. To achieve this, immunotherapy, targeted therapy and radiotherapy are applied, including the use of advanced imaging analysis techniques such as radiomics.
Dr Hendriks received several abstract awards as well as the Dirkje Postma Talent Award (incentive subsidy for her own research line) in 2019. She is (co-)author of more than 80 peer-reviewed articles.
The Young Academy
The Young Academy consists of talented researchers who share a broad interest in scientific practice, science policy and science communication. The Young Academy (De Jonge Akademie) is an independent body within the Royal Netherlands Academy of Sciences. Membership lasts for five years. Within De Jonge Akademie, Lizza Hendriks is particularly committed to early career policy, getting young people interested in and motivated for research. She will also contribute to the new Recognition and Rewards policy, with a focus on policy for physician researchers.
GROW research activities in the areas of oncology and reproductive medicine are closely interrelated, revolving around the same basic concepts and research techniques. Scientists at GROW collaborate intensively with clinicians at the Maastricht Comprehensive Cancer Centre and the Centre for Genetics, Reproduction and Child Health.
An important aim within GROW is training master's and PhD students in the fields of modern medicine and molecular life sciences.
Aafke van Montfoort
“Our results have been a wake-up call for IVF centers worldwide.”
Eline van Roekel
“Ultimately, we want personal, tailor-made lifestyle advice for every cancer survivor who needs it.”
“We are repurposing a well-known malaria-drug for our fight against cancer.”
Our liver is a special organ: if you cut away part of it, in most cases a new piece of liver will grow back. If someone has cancer in the liver, the affected part of the liver can be surgically removed. But you can only do this if at least 30% of the liver remains. For many patients whose remaining liver is too small, this means that they cannot undergo surgery. But thanks to international research from Maastricht UMC+, the treatment options for cancer in the liver have now been significantly expanded.
The UM research institute GROW and the Maastricht UMC+ Oncology Centre and have together been accredited as a Comprehensive Cancer Centre by the Organisation of European Cancer Institutes (OECI).
A radiation oncologist by training, Philippe Lambin does not limit his research to a single disease. His latest achievement: three European grants for his research on COVID-19.
A video interview with Prof. Philippe Lambin
In this ERC PoC project, we introduce fully automated software for fast, accurate, observer independent and reproducible detection and volumetric segmentation of (lung) tumours and metastases on CT images.
Andre Dekker is a clinical physicist and professor of Clinical Data Science at Maastricht University, Maastricht UMC+ and the MAASTRO Clinic. Since 2010 he has led a research group. He has over 150 publications to his name and has supervised more than 25 PhD candidates.
The research institute GROW as a whole works in close cooperation with the Maastricht University Medical Center+ (MUMC+). MUMC+ is known both nationally and internationally for its focus on prevention and taking an integrated approach to health care: from prevention, promotion of good health, and basic care, to top-level clinical diagnostics and treatment. Patient safety is our top priority in all of our endeavours. MUMC+ is part of The Netherlands Federation of University Medical Centres.
GROW Oncology is part of the Maastricht UMC+ Comprehensive Cancer Center (MCCC). The MCCC is a collaboration between Maastricht UMC+ Oncology Center (OC) and the Oncology division of GROW, of the Faculty of Health, Medicine and Life Sciences of Maastricht University. It is recognized by the Organisation of European Cancer Institutes (OECI) as one of the two top institutes in the Netherlands that offer oncological care, scientific research and education at an excellent level, working with partners inside and outside Maastricht UMC+. This places us among the best institutes not only nationally, but also internationally.
We provide patient-oriented, multidisciplinary care for oncology patients and study ways to improve the outcome of oncological (pre-)care along the continuum of prevention, diagnostics, treatment, nursing and care, and rehabilitation/post-care with a strong focus on ‘survival with preservation of function’.